ALTANA: Top line results of first one-year COPD study with Daxas
In the COPD study "RATIO/M2-112" the primary endpoint of lung function (FEV1) significantly improved with roflumilast treatment compared to placebo.The frequency of moderate and severe exacerbations was a co-primary endpoint. There was no statistically significant reduction in the rate of total exacerbations (7% reduction). The most common adverse events associated with roflumilast treatment were nausea, headache and diarrhea.
After the termination of the Daxas® collaboration with Pfizer ALTANA will continue the development of Daxas®. A marketing authorization application (MAA) for Daxas® is under evaluation by regulatory agencies in Europe.
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.